VERAXA Biotech AG (NASDAQ: VRXA) has taken a significant step in the development of its proprietary BiTAC(R)-TCE platform after receiving Scientific Advice from Germany’s Paul-Ehrlich-Institute (PEI). The regulatory feedback, announced on July 20, supports the company's proposed development strategy for its lead BiTAC(R)-TCE program, providing early guidance on biological rationale, safety assessments, and non-clinical development plan (https://ibn.fm/zBiDU).
Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping companies align their development strategies with regulatory expectations regarding safety, tolerability, and efficacy. VERAXA believes this guidance reduces development uncertainty by providing greater clarity as it advances toward clinical studies. The company's lead BiTAC(R)-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research Annual Meeting.
VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer. The PEI’s feedback specifically addressed the biological rationale and proposed non-clinical development strategy, which are critical for demonstrating safety and efficacy before human trials.
The BiTAC(R)-TCE platform represents a novel approach to cancer therapy, designed to engage T-cells to target and destroy tumor cells. With regulatory alignment achieved, VERAXA can proceed with confidence in its development plan, potentially accelerating the timeline to clinical trials. The positive feedback from PEI is a key de-risking event for the program, signaling that the regulatory agency finds the company's approach scientifically sound.
Investors and stakeholders can monitor further developments through the company’s newsroom (https://ibn.fm/VRXA). As VERAXA moves its most advanced BiTAC(R)-TCE candidate toward the clinic, the company aims to address unmet needs in oncology, particularly for cancers that are resistant to existing therapies. The regulatory milestone underscores VERAXA's commitment to advancing innovative antibody-based therapeutics.
